AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. · 2019
Read AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. by Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6335418.txt.
Introduction
Taniguchi and co-authors find a protein that blunts a key lung cancer drug. Their study appeared in Nature Communications. The drug, osimertinib, blocks faulty EGFR in lung tumors. Some patients respond poorly from the start. The team traced that resistance to a receptor called AXL. The drug itself switched AXL on, by cutting a feedback brake.
Active AXL teamed with EGFR and HER3 on the cells. That trio kept tumor cells alive under treatment. It also sped the rise of drug-tolerant cells. Blocking AXL made resistant cells die again. Adding an AXL blocker shrank tumors more in mice. Tumors with high AXL answered EGFR drugs less often in patients. The pair strategy now looks worth testing in the clinic.
Catalog record
| CREATOR | Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells By Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu Published in: Nature Communications DOI: 10.1038/s41467-018-08074-0 ABSTRACT Abstract A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback loop. Activated AXL was associated with EGFR and HER3 in maintaining cell survival and inducing the emergence of cells tolerant to osimertinib. AXL inhibition reduced the viability of EGFR-mutated lung cancer cells overexpressing AXL that were exposed to osimertinib. The addition of an AXL inhibitor during either the initial or tolerant phases reduced tumor size and delayed tumor re-growth compared to osimertinib alone. AXL was highly expressed in clinical specimens of EGFR-mutated lung cancers and its high expression was associated with a low response rate to EGFR-TKI. These results indicated pivotal roles for AXL and its inhibition in the intrinsic resistance to osimertinib and the emergence of osimertinib-tolerant cells. INTRODUCTION Non-small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) such as an exon 19 deletion and L858R mutation responds to first- and second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib, and afatinib1–4. However, 20–30% of NSCLC patients with mutated EGFR are insensitive to EGFR-TKIs and are clinically nonresponders. Several factors regarding the mechanisms of the intrinsic resistance have been previously reported including the EGFR-T790M mutation, EGFR-exon20 insertions, overexpression of hepatocyte growth factor (HGF), and BIM deletion polymorphism5–7. In addition, about 30% of responders experience early relapse within 6 months due to acquired resistance8. The gatekeeper mutation EGFR-T790M is the most common cause of acquired resistance and is detectable in approximately 50% of patients who experience acquired resistance to first- and second-generation EGFR-TKIs9,10. Osimertinib is a third-generation EGFR-TKI and inhibits EGFR that have activating mutations and/or the T790M resistance mutation, but not wild-type EGFR or other kinases, such as AXL, AKT1, or HER3; thus, it is called the mutant-EGFR-specific inhibitor11. It is approved for the treatment of EGFR-T790M-positive NSCLC patients who acquired resistance to first-generation or second-generation EGFR-TKIs. These tumors are known to acquire resistance to osimertinib by mechanisms that include acquisition of the EGFR-C797S mutation, loss of the T790M mutation, activation of a bypass pathway, and histological transformation including small cell transformation12. Much attention has been paid to the efficacy of osimertinib in the first-line setting of clinical intervention. A recent phase III clinical trial (FLAURA) demonstrated that in patients with EGFR-mutated NSCLC, progression-free survival (PFS) was longer for those treated with first-line osimertinib than for those treated with gefitinib or erlotinib13. Based on the results of the FLAURA study, first-line treatment with osimertinib is considered as one of the standard treatments for NSCLC patients with mutated EGFR. However, it was also noted that a population of patients showed intrinsic resistance and an insufficient response to osimertinib treatment, similar to that observed with other EGFR-TKIs. Moreover, even in responders, the rate of complete response is very low (3%) and residual lesions remain in the majority of the patients. Such residual lesions may serve as the basis of recurrent disease. Therefore, an understanding of the molecular mechanisms underlying intrinsic resistance and early refractoriness to osimertinib in EGFR-TKI naïve EGFR-mutated NSCLC is needed in order to establish novel therapies. A recently identified small subpopulation of reversibly drug-tolerant (DT) cells with >100-fold reduced drug sensitivity has been reported to maintain viability via IGF-1 receptor signaling14 and is supposed to contain residual lesions in mutated EGFR of NSCLC treated with first- and second-generation EGFR-TKIs. However, the molecular mechanism by which NSCLC cells emerge as DT cells to osimertinib is totally unknown. AXL is the receptor for tyrosine kinase and was first identified in 1991 in two patients with chronic myeloid leukemia15. High expression of the AXL protein in tumors is reported to be associated with poor prognosis in patients with several types of cancer including glioblastoma, breast cancer, lung cancer, and acute myeloid leukemia16–19. Overexpression of AXL has been detected more frequently in lung adenocarcinomas that harbor EGFR-activating mutations, compared with NSCLC that have wild-type EGFR20. Moreover, investigators from several studies have reported that the activation of AXL signaling in tumors is associated with acquired resistance to several targeted molecular therapy drugs and chemotherapeutic agents. However, its roles in intrinsic resistance and DT cells regarding specific targeted molecular therapy drugs remain unknown21–24. The current study was designed to clarify the molecular mechanisms underlying the induction of tolerance to osimertinib in EGFR-mutated NSCLC cells, including the roles of AXL signaling during the initial and tolerant phases. We determined that AXL interacted with other molecules, including EGFR and HER3, and maintained survival of tumor cells exposed to osimertinib. AXL inhibition using specific siRNA or chemical compounds in tumor cell-derived xenograft (CDX) models and patient-derived xenograft (PDX) models reduced the viability of osimertinib-exposed tumor cells, inhibited the emergence of DT cells, and delayed the recurrence of tumors. RESULTS Osimertinib activated AXL and re-activated HER3 and EGFR EGFR-mutated NSCLC cells, including PC-9 cells, were highly sensitive to the third-generation EGFR-TKI osimertinib. As the Cmax in patient plasma following oral administration of 80 mg of osimertinib was 635.4 nM25, we considered that 1 μM or less would be a clinically relevant concentration of osimertinib. However, approximately 20–30% of the PC-9 cells survived, even after treatment with a high concentration (1 µM) of osimertinib for 72 h (Supplementary Figure 1). To determine the mechanism by which these cells escaped the effects of osimertinib, we evaluated 43 phospho-kinases in PC-9 cells treated with or without osimertinib for 72 h using a phospho-kinase antibody array. We found that the phosphorylation of some molecules, such as HER3, MET, and AXL, increased after osimertinib treatment (Fig. 1a). We therefore hypothesized that tolerance to osimertinib may be caused by a survival signal via these proteins. Kinetic analysis revealed that while phosphorylation of EGFR was remarkably inhibited by osimertinib at 4 h, it was measurably re-activated at 72 h (Fig. 1b). The phosphorylation of HER3 and MET was also inhibited by osimertinib at 4 h, but the phosphorylation of these proteins was re-activated at 24 h and the reactivation gradually increased through 72 h. On the other hand, while AXL was not constitutively phosphorylated, its phosphorylation was induced by osimertinib at 4 h and increased through 72 h. Phosphorylation of ERK, a downstream molecule of EGFR, was remarkably inhibited by osimertinib at 4 h and the suppression was maintained through 72 h. In sharp contrast, AKT, another downstream molecule of EGFR signaling, was slightly inhibited by osimertinib at 4 h and was re-activated at 24 h. These results suggested that osimertinib exposure may have activated AXL and thereby re-activated HER3, MET, and EGFR in PC-9 cells. [Figure: Osimertinib activated AXL in EGFR-mutated NSCLC cells in vitro. a Human tyrosine kinase phosphorylation array analysis of PC-9 cells in the presence or absence of osimertinib (100 nmol/L) for 72 h. b PC-9 cells were treated with osimertinib (100 nmol/L), lysed, and the indicated proteins detected